Form 8-K Zynerba Pharmaceuticals, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
UPDATE: Needham & Company Downgrades Zynerba Pharmaceuticals (ZYNE) to Hold
July 1, 2020 7:18 AM EDT(Updated - July 1, 2020 7:22 AM EDT)
(updating comment)
Needham & Company analyst Serge Belanger downgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Buy to Hold.
The analyst comments "Zygel missed primary and secondary endpoints in the pivotal ph 3 CONNECT-FX trial, but met the... More
